Cited by 2,251Clinical practice guidelines implementationHealth Promotion and Cardiovascular PreventionCoronary Interventions and Diagnostics

The DOI matches its Crossref record.

European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)

De Backer, G·2003·European Heart Journal

DOI 10.1016/s0195-668x(03)00347-6

Open this paper in CoChat — free account

Abstract

Guidelines aim to present all the relevant evidence on a particular issue in order to help physicians to weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be helpful in everyday clinical decision-making. A great number of guidelines have been issued in recent years by different organizations-European Society of Cardiology (ESC), American Heart Association (AHA), American College of Cardiology (ACC), and other related societies. By means of links to web sites of National Societies several hundred guidelines are available. This profusion can put at stake the authority and validity of guidelines, which can only be guaranteed if they have been developed by an unquestionable decision-making process. This is one of the reasons why the ESC and others have issued recommendations for formulating and issuing guidelines. In spite of the fact that standards for issuing good quality guidelines are well defined, recent surveys of guidelines published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied with in the vast majority of cases. It is therefore of great importance that guidelines and recommendations are presented in formats that are easily interpreted. Subsequently, their implementation programmes must also be well conducted. Attempts have been made to determine whether guidelines improve the quality of clinical practice and the utilization of health resources. In addition, the legal implications of medical guidelines have been discussed and examined, resulting in position documents, which have been published by a specific Task Force.

Integrity signals

Registry

Crossref · 10.1016/s0195-668x(03)00347-6

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.037 · Cited by 8,191
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
2007 Guidelines for the Management of Arterial Hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cífková, R., Fagard, R. H., Germanò, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,870
Self-citation
2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Self-citation
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
2007 Guidelines for the management of arterial hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cifkova, R., Fagard, R., Germano, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,410
Self-citation
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes
Bassand, J., Hamm, C. W., Ardissino, D., Boersma, E. H., Budaj, A., Fernández‐Avilés, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., Wallentin, L. C., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,860
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary
Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,644
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Assessment of Coronary Artery Disease by Cardiac Computed Tomography
Budoff, M. J., Achenbach, S. S., Blumenthal, R. S., Carr, J. J., Goldin, J. G., Greenland, P., Guerci, A. D., Lima, J. A. C., Rader, D. J., Rubin, G. D., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.178458 · Cited by 1,400
One-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382
Guidelines on the management of stable angina pectoris: executive summary
Authors/Task Force Members, Fox, K. M., Garcia, M. A. A., Ardissino, D., Buszman, P. E., Camici, P. G., Crea, F., Daly, C., Backer, G. D., Hjemdahl, P., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl001 · Cited by 1,332
Self-citation
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
Lloyd-Jones, D. M., Leip, E. P., Larson, M. G., D’Agostino, R. B., Beiser, A., Wilson, P. W. F., Wolf, P. A., & Levy, D. (2006) · Circulation · doi:10.1161/circulationaha.105.548206 · Cited by 1,298
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Prepared, B. (2005) · Heart · doi:10.1136/hrt.2005.079988 · Cited by 1,223
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schächter, M. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,247
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.178233 · Cited by 1,080
Resting Heart Rate in Cardiovascular Disease
Fox, K., Borer, J. S., Camm, A. J., Danchin, N., Ferrari, R., Lopez Sendon, J. L., Steg, P. G., Tardif, J.-C., Tavazzi, L., & Tendera, M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.079 · Cited by 1,062
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity
Malmberg, K., Rydén, L., Wedel, H., Birkeland, K., Bootsma, A., Dickstein, K., Efendic, S., Fisher, M., Hamsten, A., Herlitz, J., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi199 · Cited by 1,048
Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study
Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., May, M., & Brindle, P. (2007) · British medical journal · doi:10.1136/bmj.39261.471806.55 · Cited by 1,070
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010
Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010
Recommendations for competitive sports participation in athletes with cardiovascular disease: A consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology
Pelliccia, A. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi325 · Cited by 983
Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial
‡ (2005) · The Lancet · doi:10.1016/s0140-6736(05)67661-1 · Cited by 949
Postprandial Hyperglycemia and Diabetes Complications
Ceriello, A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.1 · Cited by 945
Dietary n−6 and n−3 polyunsaturated fatty acids: From biochemistry to clinical implications in cardiovascular prevention
Russo, G. L. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.10.020 · Cited by 843
Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries
Kotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., & Keil, U. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60330-5 · Cited by 833
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
Kotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812
Self-citation
Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study
Booth, G. L., Kapral, M. K., Fung, K., & Tu, J. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68967-8 · Cited by 782
The Worldwide Environment of Cardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy Issues
Laslett, L. J., Alagona, P., Clark, B. A., Drozda, J. P., Saldivar, F., Wilson, S. R., Poe, C., & Hart, M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.002 · Cited by 801
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 716
Cardiovascular Risk Prediction: Basic Concepts, Current Status, and Future Directions
Lloyd-Jones, D. M. (2010) · Circulation · doi:10.1161/circulationaha.109.849166 · Cited by 705
Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
Lavie, C. J., Milani, R. V., Mehra, M. R., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.084 · Cited by 644
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
(2014) · The Lancet · doi:10.1016/s0140-6736(14)61212-5 · Cited by 623
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women
Ingelsson, E., Schaefer, E. J., Contois, J. H., McNamara, J. R., Sullivan, L., Keyes, M. J., Pencina, M. J., Schoonmaker, C., Wilson, P. W. F., D’Agostino, R. B., et al. (2007) · JAMA · doi:10.1001/jama.298.7.776 · Cited by 608
Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction
Langsted, A., Freiberg, J. J., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.108.804146 · Cited by 588
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Rapezzi, C., Biagini, E., & Branzi, A. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm498 · Cited by 593
The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence
WALLDIUS, G., & JUNGNER, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01643.x · Cited by 583
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) · The Lancet · doi:10.1016/s0140-6736(10)60310-8 · Cited by 558
Expert consensus document on ?-adrenergic receptor blockersThe Task Force on Beta-Blockers of the European Society of Cardiology
(2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.002 · Cited by 557
Cardiac computed tomography: indications, applications, limitations, and training requirements: Report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology
Schroeder, S., Achenbach, S., Bengel, F., Burgstahler, C., Cademartiri, F., de Feyter, P. J., George, R. T., Kaufmann, P. A., Kopp, A. F., Knuuti, J. M., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm544 · Cited by 550
Multiple risk factor interventions for primary prevention of coronary heart disease
Ebrahim, S. B. J., Taylor, F. C., Ward, K. J., Beswick, A. D., Burke, M., & Smith, G. D. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001561.pub3 · Cited by 559
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 526
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525
How to assess physical activity? How to assess physical fitness?
Vanhees, L., Lefevre, J., Philippaerts, R. M., Martens, M., Huygens, W., Troosters, T., & Beunen, G. P. (2005) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000161551.73095.9c · Cited by 595
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel
Barter, P. J., Ballantyne, C. M., Carmena, R., Cabezas, M. C., Chapman, M. J., Couture, P., Graaf, J. D., Durrington, P. N., Færgeman, O., Frohlich, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 465
Post-Myocardial Infarction Heart Failure
Bahit, M. C., Kochar, A., & Granger, C. B. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2017.09.015 · Cited by 490
Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review
Brindle, P., Beswick, A. D., Fahey, T. P., & Ebrahim, S. B. J. (2006) · Heart · doi:10.1136/hrt.2006.087932 · Cited by 450
Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial
Montorsi, P., Ravagnani, P. M., Galli, S., Rotatori, F., Veglia, F., Briganti, A., Salonia, A., Dehò, F., Rigatti, P., Montorsi, F., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl142 · Cited by 417
Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence
Lorente‐Cebrián, S., Costa, A. G. V., Navas‐Carretero, S., Zabala, M., Martínez, J. A., & Moreno-Aliaga, M. J. (2013) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-013-0265-4 · Cited by 427
Global Secondary Prevention Strategies to Limit Event Recurrence After Myocardial Infarction: Results of the GOSPEL Study, a Multicenter, Randomized Controlled Trial From the Italian Cardiac Rehabilitation Network
Giannuzzi, P. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.20.2194 · Cited by 411
Comparing performances of logistic regression, classification and regression tree, and neural networks for predicting coronary artery disease
Ömürlü, İ. K., Türe, M., & Kurum, A. T. (2006) · Expert Systems with Applications · doi:10.1016/j.eswa.2006.09.004 · Cited by 406
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 409
Dietary reference intakes for DHA and EPA
Kris‐Etherton, P. M., Grieger, J. A., & Etherton, T. D. (2009) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2009.05.011 · Cited by 413
Apolipoprotein B and apolipoprotein A‐I: risk indicators of coronary heart disease and targets for lipid‐modifying therapy
Walldius, G., & Jungner, I. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01276.x · Cited by 395
Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology
Stramba‐Badiale, M., Fox, K. M., Priori, S. G., Collins, P. D., Daly, C., Graham, I. D., Jonsson, B., Schenck-Gustafsson, K. G., & Tendera, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi819 · Cited by 393
The sympathetic nervous system and the metabolic syndrome
Mancia, G., Bousquet, P., Elghozi, J. L., Esler, M., Grassi, G., Julius, S., Reid, J., & Van Zwieten, P. A. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e328048d004 · Cited by 385
Principles for National and Regional Guidelines on Cardiovascular Disease Prevention
Smith, S. C., Jackson, R., Pearson, T. A., Fuster, V., Yusuf, S., Færgeman, O., Wood, D. A., Alderman, M. H., Horgan, J., Home, P., et al. (2004) · Circulation · doi:10.1161/01.cir.0000133427.35111.67 · Cited by 369
Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study
Sundström, J., Risérus, U., Byberg, L., Zethelius, B., Lithell, H., & Lind, L. (2006) · BMJ · doi:10.1136/bmj.38766.624097.1f · Cited by 375
Metabolic syndrome and cardiovascular disease
Qiao, Q., Gao, W., Zhang, L., Nyamdorj, R., & Tuomilehto, J. O. (2007) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/000456307780480963 · Cited by 383
Alterations in the gut microbiome and metabolism with coronary artery disease severity
Liu, H., Chen, X., Hu, X., Niu, H., Tian, R., Wang, H., Pang, H., Jiang, L., Qiu, B., Chen, X., et al. (2019) · Microbiome · doi:10.1186/s40168-019-0683-9 · Cited by 378
Position of the American Dietetic Association and Dietitians of Canada: Dietary Fatty Acids
Kris‐Etherton, P. M., Innis, S. M., Assocition, A. D., & Canada, D. O. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.024 · Cited by 372
C‐reactive protein and coronary heart disease: a critical review
Casas, J. P., Shah, T., Hingorani, A. D., Danesh, J., & Pepys, M. B. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02015.x · Cited by 367
Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE Association Review
Austin, M. A. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh237 · Cited by 361
Health literacy is associated with health behaviour and self-reported health: A large population-based study in individuals with cardiovascular disease
Aaby, A., Friis, K., Christensen, B., Rowlands, G., & Maindal, H. T. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317729538 · Cited by 360
2007 ESH‐ESC Guidelines for the management of arterial hypertension
Mansia, G., Backer, G. D., Dominiczak, A. F., Cífková, R., Fagard, R. H., Germanò, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Blood Pressure · doi:10.1080/08037050701461084 · Cited by 361
Self-citation
Primary Prevention of Cardiovascular Diseases With Statin Therapy
Thavendiranathan, P. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.21.2307 · Cited by 349
Incorporation and Clearance of Omega-3 Fatty Acids in Erythrocyte Membranes and Plasma Phospholipids
Cao, J., Schwichtenberg, K., Hanson, N. Q., & Tsai, M. Y. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.072322 · Cited by 355
New Risk Factors for Atherosclerosis and Patient Risk Assessment
Fruchart, J., Nierman, M. C., Stroes, E. S. G., Kastelein, J. J. P., & Duriez, P. (2004) · Circulation · doi:10.1161/01.cir.0000131513.33892.5b · Cited by 354
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
Cardiovascular benefits of omega-3 fatty acids
Vonschacky, C., & Harris, W. S. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.08.019 · Cited by 343
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseaseThe Task Force on ACE-inhibitors of the European Society of Cardiology
Lopez-Sendon, J. L., Swedberg, K. B., McMurray, J. J. V., Tamargo, J. L., Maggioni, A. P., Dargie, H., Tendera, M., Waagstein, F., Kjekshus, J., Lechat, P. P., et al. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.003 · Cited by 331
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
Work-Related Psychosocial Factors and the Development of Ischemic Heart Disease: A Systematic Review
Eller, N. H., Netterstrøm, B., Gyntelberg, F., Kristensen, T. S., Nielsen, F., Steptoe, A., & Theorell, T. (2009) · Cardiology in Review · doi:10.1097/crd.0b013e318198c8e9 · Cited by 323
Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA study
Marrugat, J., Subirana, I., Comín, E., Cabezas, C., Vila, J., Elosúa, R., Nam, B., Ramos, R., Sala, J., Solanas, P., et al. (2006) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2005.038505 · Cited by 324
Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
SHARP Collaborative Group (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.08.012 · Cited by 319
Ambulatory Blood Pressure and Mortality: A Population-Based Study
Hansen, T. W., Jeppesen, J., Rasmussen, S., Ibsen, H., & Torp-Pedersen, C. (2005) · Hypertension · doi:10.1161/01.hyp.0000160402.39597.3b · Cited by 317
p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease
Meijers, B. K. I., Claes, K. J., Bammens, B., de Loor, H., Viaene, L., Verbeke, K., Kuypers, D. R. J., Vanrenterghem, Y. F. C., & Evenepoel, P. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07971109 · Cited by 320
Lipid Treatment Assessment Project 2
Waters, D. D., Brotons, C., Chiang, C.-W., Ferrières, J., Foody, J. M., Jukema, J. W., Santos, R. D., Verdejo, J., Messig, M., McPherson, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.838466 · Cited by 305
Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease
Lees, J. S., Welsh, C. E., Celis-Morales, C. A., Mackay, D., Lewsey, J., Gray, S. R., Lyall, D. M., Cleland, J. G. F., Gill, J. M. R., Jhund, P. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0627-8 · Cited by 319
The EUROPA trial
Fox, K. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14974-4 · Cited by 297
The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D:A:D Study
Law, M. G., Friis‐Møller, N., El-Sadr, W. M., Weber, R. K., Reiss, P., Monforte, A. D., Thiébaut, R., Morfeldt, L., Wit, S. D., Pradier, C., et al. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00362.x · Cited by 295
An update on regional variation in cardiovascular mortality within Europe
Müller‐Nordhorn, J., Binting, S., Roll, S., & Willich, S. N. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm604 · Cited by 296
“The current European Guidelines on Cardiovascular Disease Prevention in Clinical Practice take national variation in cardiovascular mortality into account.(6) In the primary prevention setting, the overall 10-year cardiovascular risk is estimated for different risk factor combinations.”
Background
Fasting Time and Lipid Levels in a Community-Based Population
Sidhu, D., & Naugler, C. T. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.3708 · Cited by 294
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
Walldius, G., Jungner, I., AASTVEIT, A. H., Holme, I., Furberg, C. D., & Sniderman, A. D. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.254 · Cited by 287
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3494 · Cited by 310
Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study.
Hallan, S. I., Astor, B., Romundstad, S., Aasarød, K., Kvenild, K., & Coresh, J. (2007) · PubMed · doi:10.1001/archinte.167.22.2490 · Cited by 284
Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-based prospective study
Warensjö, E., Sundström, J., Vessby, B. O., Cederholm, T., & Risérus, U. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.1.203 · Cited by 281
Omega-3 fatty acids and cardiovascular disease: A case for omega-3 index as a new risk factor
Harris, W. S. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.01.013 · Cited by 287
A Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischaemic heart disease
Lindeberg, S., Jönsson, T., Granfeldt, Y., Borgstrand, E., Soffman, J., Sjöström, K., & Ahrén, B. (2007) · Diabetologia · doi:10.1007/s00125-007-0716-y · Cited by 273
Dietary Omega-3 Fatty Acid Intake and Cardiovascular Risk
Psota, T., Gebauer, S. K., & Kris‐Etherton, P. M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.022 · Cited by 275
Stress Reduction Prolongs Life in Women With Coronary Disease: The Stockholm Women’s Intervention Trial for Coronary Heart Disease (SWITCHD)
Orth-Gomér, K., Schneiderman, N., Wang, H.-X., Walldin, C., Blom, M., & Jernberg, T. (2009) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.812859 · Cited by 266
Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study
O’Donnell, C. J., & Elosúa, R. (2008) · Revista Española de Cardiología · doi:10.1157/13116658 · Cited by 282
Cardiovascular Risk Factors. Insights From Framingham Heart Study
O’Donnell, C. J., & Elosúa, R. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(08)60118-8 · Cited by 272
Measurement of carotid intima–media thickness to assess progression and regression of atherosclerosis
de Groot, E., van Leuven, S. I., Duivenvoorden, R., Meuwese, M. C., Akdim, F., Bots, M. L., & Kastelein, J. J. P. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1163 · Cited by 263
Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis
Cavero-Redondo, I., Peleteiro, B., Álvarez-Bueno, C., Rodriguez-Artalejo, F., & Martínez-Vizcaíno, V. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-015949 · Cited by 260
Effect of Intensive Versus Standard Lipid-Lowering Treatment With Atorvastatin on the Progression of Calcified Coronary Atherosclerosis Over 12 Months
Schmermund, A., Achenbach, S. S., Budde, T., Buziashvili, Y. I., Förster, A., Friedrich, G. J., Henein, M., Kerkhoff, G., Knollmann, F. D., Kukharchuk, V. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.568147 · Cited by 254
Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry
Cacoub, P., Abola, M. T. B., Baumgärtner, I., Bhatt, D. L., Creager, M. A., Liau, C., Goto, S., Röther, J., Steg, P. G., & Hirsch, A. T. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.10.023 · Cited by 257

Authors: De Backer, G.
Venue: European Heart Journal
Publisher: Oxford University Press (OUP)
Published: 2003-09
Volume: 24
Issue: 17
Pages: 1601-1610
ISSN: 0195-668X (ISSN-L)
DOI: 10.1016/s0195-668x(03)00347-6
OpenAlex: W2153788691
Cited by: 2,251
References: 0
Citations by year: 2026: 4 · 2025: 7 · 2024: 15 · 2023: 19 · 2022: 12 · 2021: 55 · 2020: 64 · 2019: 92 · 2018: 65 · 2017: 67 · 2016: 51 · 2015: 57 · 2014: 78 · 2013: 87 · 2012: 98
FWCI: 206.41
Type: journal article
Language: en
Open access: closed
Locations: European Heart Journal (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: cardiovascular disease prevention, guideline development methodology, quality of evidence, clinical decision-making, guideline implementation, cardiovascular risk management
MeSH terms: Smoking Prevention, Blood Pressure, Cardiovascular Diseases, Diagnostic Imaging, Diet, Europe, Health Priorities, Humans, Lipids, Risk Factors, Exercise, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks